EXTRAPULMONARY NEUROENDOCRINE CARCINOMA
Clinical trials for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRAPULMONARY NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple-drug attack targets rare, aggressive neuroendocrine cancers
Disease control Not yet recruitingThis study tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare and fast-growing type of cancer called large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The goal is to see …
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Engineered immune cells take aim at deadly lung cancer
Disease control Not yet recruitingThis early-phase study tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells that carry a protein called B7-H3. The study includes up to 40 adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC